1-L-myo-Inositol-1-phosphate synthase catalyzes the conversion of D-glucose 6-phosphate to 1-L-myo-inositol-1-phosphate (MIP), the first and rate-limiting step in the biosynthesis of all inositol-containing compounds. It involves an oxidation, intramolecular aldol cyclization, and reduction. We have determined the first crystal structure of MIP synthase. We present structures of both the NAD-bound enzyme and the enzyme bound to an inhibitor, 2-deoxy-glucitol-6-phosphate. While 58 amino acids are disordered in the unbound form of the enzyme in the vicinity of the active site, the inhibitor nucleates the folding of this domain in a striking example of induced fit, serving to completely encapsulate it within the enzyme. Three helices and a long ␤-strand are formed in this process. We postulate a mechanism for the conversion based on the structure of the inhibitorbound complex.
Most enzymes consist of a well defined active site cleft or pocket presented on the surface of the protein. Substrates then freely diffuse into and out of the active site. In some cases, such as the HIV protease 1 (1, 2) , the active site can be sequestered upon binding by a structural rearrangement of the enzyme. Here we report the first crystal structures of both bound and unbound Saccharomyces cerevisiae 1-L-myo-inositol-1-phosphate synthase (MIP synthase; EC 5.5.1.4), an enzyme that appears to require its substrate to nucleate the folding of the active site around itself, causing encapsulation of the substrate within the enzyme.
Inositol-containing compounds play critical and diverse biological roles including signal transduction and second messenger signaling, stress response, and cell wall biogenesis (3) (4) (5) (6) . The biosynthesis of inositol follows a common pathway involving first the conversion of glucose 6-phosphate to 1-L-myoinositol-1-phosphate (MIP) catalyzed by MIP synthase, followed by dephosphorylation catalyzed by MIP phosphatase (5) . The synthesis of MIP is both the first committed and ratelimiting step in this pathway (5) . Significant biosynthesis of inositol has been detected in organs where a significant blood barrier exists, such as the testes or brain (7) (8) (9) (10) (11) . Significantly, reduction of the brain inositol pool by inhibition of MIP phosphatase has been suggested to be the mode of action for lithium in the treatment of bipolar disorder (12) (13) (14) (15) . Recent in vivo results in yeast suggest that valproate, a drug used in the treatment of depression, bipolar disorder, and seizure disorder, may act by inhibition of MIP synthase, thus lowering neuronal inositol pools similar to the action of lithium (16) . Regulation of inositol biosynthesis itself may play an important role in the regulation of second messenger signaling.
MIP synthase has been characterized and cloned from a diversity of organisms including yeast, plants, flies, humans, Archaebacteria, and bacteria (5, (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . The eucaryotic enzymes are remarkably conserved throughout their length with better than 45% identity from yeast to flies (5) (Fig. 1a) . In all cases, the enzyme displays modest catalytic activity with turnover numbers ranging from 3 to 13 M/min/mg of enzyme and substrate K m values in the 100 M range (5, 18) . A significant collection of both biochemical and chemical data have coalesced to the reaction path first proposed by Loewus and colleagues ( Fig. 1b) (5, (27) (28) (29) (30) (31) . Several inhibitor studies are consistent with the idea that the enzyme first binds the open acyclic tautomer of the substrate glucose 6-phosphate, followed by oxidation to the C5-keto intermediate (intermediate B in Fig.  1b) (32) . Frost and co-workers (32) proposed that enolization is promoted by proton extraction via the substrate phosphate, consistent with the phosphate binding in a transoid conformation. Intramolecular aldol cyclization followed by rereduction of the C5-ketone completes the formation of the product. None of the intermediates have been isolated or trapped, suggesting that all intermediates are tightly bound and not released until the final reduction to myo-inositol 1-phosphate (33) (34) (35) . The enzyme thus catalyzes three distinct steps, an oxidation, intramolecular aldol cyclization, and finally reduction in the same active site with no apparent dissociation of intermediates.
Major questions still remain regarding the mechanism of this enzyme, especially regarding the nature of the aldol cyclization. Typically, enzymes that utilize an aldol cyclization reaction can be categorized as either a type I or type II aldolase. In terms of yeast MIP synthase, it is neither a type I aldolase, which involves a covalent Schiff base intermediate, nor a type II aldolase, which involves a divalent cation such as zinc or manganese acting as Lewis acid (11, 36 -39) . Instead, the enzyme is activated 5-fold by ammonium ions (18) . On the other hand, MIP synthase from Archaebacteria fulgidus requires divalent cations and therefore is thought to be a type II aldolase. This is quite surprising, considering the high sequence homology between the enzymes (53% similarity) (18) . It is far more common to find enzymes with completely divergent sequences and even completely different three-dimensional structures using identical mechanisms than the converse.
To better understand the molecular details of this complex and critical biological transformation, we have determined the structures of yeast MIP synthase bound to NAD to 2. tural details of the MIP synthase active site may also lead to the development of better inhibitors of the enzyme having valproate-like psychotherapeutic benefits.
EXPERIMENTAL PROCEDURES
Crystallization, Data Collection, Phasing, and Refinement of MIP Synthase-The yeast MIP synthase enzyme was isolated, purified, and crystallized as previously described by Stein and Geiger (40) . The structure was solved by multiwavelength anomalous dispersion phasing at the selenium edge. A three-wavelength multiwavelength anomalous dispersion data set was collected on beamline 19-ID of the Structural Biology Center (Advanced Photon Source, Argonne, IL), and the data were processed using HKL2000 (Table I) (41) . 18 of the 22 possible selenium positions were located using automated Patterson search routines implemented in SOLVE (42) . Heavy atom refinement and calculation of the resulting interpretable electron density map was also performed using SOLVE. After solvent flattening using the CCP4 package, the map was traced using O and TURBO-FRODO and refined using CNS (43) (44) (45) . After multiple rounds of refinement, the final model at 2.4 Å has an R and R-free value of 20.5 and 24.3% respectively. The final model contains residues 10 -351 and 410 -533 for both molecules in the asymmetric unit and 543 water molecules. All but six (1.1%) residues lie within the most favored or allowed regions of the Ramachandran plot. The parameters evaluated by PROCHECK (46) are well within the bounds established from well refined structures at the equivalent resolution (Table I) .
Crystallization, Data Collection, and Refinement of the MIP Synthase⅐NADH⅐dgtolP Complex-The inhibitor-bound complex was crystallized like the native except that both 10 mM dgtolP and 20 mM NAD were added to the protein solution at least 12 h before crystallization trials were initiated. High resolution data were collected and processed as described above to a nominal resolution of 2.2 Å (Table II) . After an initial round of refinement using CNS, clear electron density was evident for the inhibitor, NADH, and most of the previously disordered region (residues 352-409) in a 1.2 contoured map calculated at 2.5-Å resolution. Subsequent rounds of rebuilding, refinement, and resolution extension resulted in the final structure. The reduction of NAD to NADH and oxidation of C5 to the ketone was discernible in the electron density map. The final model contains residues 9 -533, 618 water molecules, NADH, dgtolP, and one ammonium ion (per monomer). It has an R and R-free value of 20.8 and 27.6%, respectively. 97.8% of the entire structure lie within the most favored or allowed regions of the Ramachandran plot. The parameters evaluated by PRO-CHECK are well within the bounds established from well refined structures at the equivalent resolution. Fig. 5b shows the final 2F o Ϫ F c electron density map contoured at 1.2 in the vicinity of the active site.
RESULTS AND DISCUSSION
The Structure of the MIP Synthase Tetramer-MIP synthase is a homotetramer both in solution and in the solid state ( Fig.  2 ) (5, 47). As shown in Fig. 2 , the tetramer has 222 symmetry with a noncrystallographic 2-fold axis relating the two molecules in the asymmetric unit and a crystallographic 2-fold axis relating the two molecules at the top of Fig. 2 (the red and blue monomers) with those at the bottom (the two green monomers). The interface between the noncrystallographic dimer (the dimerization interface) is both large and intricate, burying 11,700 Å 2 of surface area between the two. Interactions are made throughout the molecule, from the top of the structure to the bottom. Although not as involved as the dimerization interface, the interface between the dimers is also significant, burying about 6,000 Å 2 of surface area. All the interactions in this interface emanate from the juxtaposition of two large ␤-sheets, one from each dimer. The surface is composed mostly of hydrophobic residues, making it unlikely that there is any dissociation of the tetramer.
The Structure of the MIP Synthase Monomer-The MIP synthase monomer can be divided into three major domains, each with its own distinct function (Fig. 3a) . A central domain consisting of the N and C termini makes the majority of contacts between monomers across the noncrystallographic 2-fold and stabilizes the relative orientation of the other two domains. A domain reminiscent of an NAD-binding or Rossmann fold domain (encompassing residues 66 -326) contains a parallel fivestranded ␤-sheet, four surrounding helices, and two additional extensions, one that completely surrounds the adenine of NAD preventing ready dissociation of the nucleotide (residues 149 -215) and one insertion between the first and second strands of the Rossmann fold (residues 93-140) that folds into the central domain of the enzyme. The third domain (encompassing residues 327-441) contains the ␤-sheet involved in the tetramerization interface and the catalytic domain. Numerous interactions between these three domains create a rigid overall structure with little possibility for relative motion between c Figure of merit ϭ ͉¥P(␣)e i ␣/¥P(␣)͉, where ␣ is the phase and P(␣) is the phase probability.
, where all reflections belong to a test set of 10% randomly selected data.
Also, all refinement statistics were calculated with a 2 cut-off. Also, all refinement statistics were calculated with a 2 cut-off. these domains. Inspection of Fig. 1a indicates that although all eucaryotic MIP synthases are highly conserved throughout their length and will almost certainly have very similar structure throughout, a significant portion of the N terminus is missing in the A. fulgidus enzyme. This will lead to differences in the structure of the central domain of this enzyme relative to that seen here. The fold of MIP synthase bears some resemblance to that of diaminopimilate dehydrogenase, especially the structure and relative position of the catalytic domain and the Rossmann fold domain (48, 49) . Diaminopimilate dehydrogenase is a dimer in solution and shares a similar dimerization interface with MIP synthase as well.
NAD Binding-Interaction of MIP synthase with NAD is similar to that seen in other Rossmann fold NAD-binding enzymes. NAD runs across the bottom of the parallel ␤-sheet of the nucleotide-binding domain. Instead of the more common GXGXXG motif, MIP synthase has a GXGGXXG motif (GLG-GNNG, encompassing residues 72-78) in the loop connecting the ␤ 3 strand and ␣ 1 helix. This loop makes interactions with the phosphodiester backbone as seen in other structures. The amide of the nicotinamide is rotated to the phosphodiester side and makes a tight hydrogen bond with the phosphodiester backbone, serving to stabilize this orientation. Numerous interactions between NAD and the enzyme are observed throughout the nucleotide-binding and catalytic domains of MIP synthase. In turn, most of these residues are highly conserved among the eucaryotic enzymes. The nucleotide binding domains of the archaebacterial enzymes are less highly conserved, and many of the interacting residues are different in these enzymes. The significance of these differences must await the structure determination of these enzymes.
The Structural Changes in MIP Synthase That Occur upon Inhibitor Binding-The 2.4-Å structure of MIP synthase as purified from E. coli (40) revealed partial NAD occupancy in the NAD-binding domain and allowed us to define the catalytic region of the enzyme based on the position of the nicotinamide. Surprisingly, the nicotinamide was completely exposed on the surface of the structure with no discernible active site cleft or cavity surrounding it (Fig. 3b) . Additionally, we were unable to locate electron density for 58 residues, from 352 to 409. These residues represent the most conserved region of the enzyme, sharing 73% identity from Archaebacteria to humans. The beginning and end of this region are located near the putative catalytic region defined by the position of the nicotinamide. In an effort to shed light on this unusual combination of observations, we grew crystals of MIP synthase in the presence of 10 mM dgtolP (Fig. 1b) . We were able to obtain crystals using conditions identical to those previously used, with identical unit cell dimensions and space group, although the diffraction was improved by almost 0.2 Å to 2.2-Å resolution. Electron density for the inhibitor was found in the vicinity of the putative active site, and additional unambiguous electron density was found for every residue in the disordered region from 352 to 409. These residues create an entire subdomain that folds around the inhibitor, completely encapsulating it (Fig. 4a) . Once this subdomain is ordered, there is no access to the interior of the active site, even for a solvent molecule (Fig. 4b) . Thus, a rather large cavity is created within the structure of the enzyme. We conclude that the formation of the MIP active site represents an extreme example of induced fit, where the substrate nucleates the folding of its own active site and its complete encapsulation within the enzyme. Whereas it would appear from the two structures we have on hand that this subdomain is ordered exclusively by inhibitor binding, we cannot rule out the possibility that at least some of the region may be stabilized by full occupancy of NAD. Stabilization by NAD may be of particular importance for ␣ 13 , because it makes the lion's share of NAD contacts in the newly ordered domain (Fig.  1a) . Although there is little change in the structure of the rest of MIP synthase upon inhibitor binding, the loop that includes residues 191-198 is an exception, since the folding of the new catalytic domain forces this loop to flip out and create space for the newly ordered region (Fig. 4c) . Several new contacts are made between this loop and the newly ordered subdomain as shown in Fig. 4c .
The Interactions between MIP Synthase and dgtolP-The inhibitor, dgtolP, is bound to the enzyme in an extended conformation, with the phosphate group in a transoid conformation relative to the inhibitor carbon backbone (Fig. 5, a and b) . This conformation is consistent with several inhibitor studies conducted by Frost and co-workers (32). First, although there are many examples of exclusively acyclic substrate mimics that make good inhibitors of the enzyme, no exclusively cyclic mim- , and Gln 325 (clockwise). This figure was made using SETOR (56) . c, modeling of dgtolP in the active site of MIP synthase to a conformation consistent with aldol cyclization and subsequent reduction at C5. Atoms are colored by atom type as in Fig. 5a . dgtolP bonds are aqua, and NADH bonds are gold. Similarly, the new interactions are labeled red in their residue name.
ics of the substrate bind the enzyme with any affinity (32). The conclusion from these studies was that MIP synthase binds exclusively the acyclic form of the substrate, glucose 6-phosphate. This was unexpected, because the equilibrium favors the cyclic tautomer by at least 100:1. Second, while 2-deoxy-Dglucitol 6-(E)-vinylhomophosphonate, an (E)-vinyl-phosphonate substrate mimic, strongly inhibits yeast MIP synthase, the (Z)-enantiomer has no affinity for the enzyme (32) . Given these data, it is not surprising to find dgtolP bound in an acyclic, extended conformation with the phosphate in a transoid conformation. Consistent with the biochemical data, we find dgtolP to be oxidized to the C5-ketone derivative and the NAD to be reduced to NADH (32) . Evidently, we have a mimic of the first intermediate in the reaction pathway, after the first oxidation, but before enolization and intramolecular aldol cyclization. The dgtolP is well nestled in the cavity, with each of the hydroxyl groups hydrogen-bonded to a highly conserved residue of MIP synthase. In fact, all but one of these residues is completely conserved in all MIP synthases. The exception is Gln 325 , which is conserved in all eucaryotic MIP synthases but is changed to Glu 230 in the A. fulgidus enzyme. This residue interacts with O1 of the inhibitor, which would be an aldehyde oxygen in the substrate. It is possible that the substrate is bound in a less extended conformation, at least in the Archaebacterial enzyme, since the aldehyde would not hydrogen bond to the glutamate unless the glutamate was protonated. A large hydrophobic surface consisting of residues Leu 352 , Leu 360 , Ile 400 , and Ile 402 aligns one side of the binding cavity. These hydrophobic residues are completely conserved throughout evolution. Since valproate (2-propylpentanoic acid) is quite hydrophobic, it is likely that this surface plays an important role in its binding to the enzyme. Further mutational and biochemical assays are necessary to confirm this proposal.
A relatively large 4 peak of electron density was located proximal to the phosphate group of the inhibitor and the residues Asp 438 and Asn 354 (Fig. 5, a and b) . This peak is not seen in the unbound structure, since Asn 354 is disordered. Based on its proximity both to Asp 438 and the phosphate, we postulate that this density is due to a monovalent cation, probably an ammonium ion. We believe this to be ammonium, because ammonium ions increase the rate of the enzyme 5-fold and because ammonium ions are present in the crystallization solution (40) . This putative ammonium ion is roughly tetrahedrally coordinated to Asp 438 , Asn 354 , a phosphate oxygen, and O6 of the inhibitor. It is interesting to note that while Asp 438 is absolutely conserved in all MIP synthases from Archaebacteria to human, Asn 354 , while absolutely conserved in eucaryotic MIP synthases, is occupied by Asp 259 in A. fulgidus. We postulate that the addition of a second charged ligand changes the cation specificity from monovalent to divalent and may explain why A. fulgidus MIP synthase requires a divalent cation such as Zn 2ϩ or Mn 2ϩ for activity. There are two other enzymes that have both NAD and a metal ion in their active site: dehydroquinate synthase and alcohol dehydrogenase. When the nicotinamide rings of these two enzymes are overlaid, the metal ion positions are almost identical. Further, when the nicotinamide rings of dehydroquinate synthase and MIP synthase are overlaid, the position of the ammonium ion is within 1.5 Å of the dehydroquinate synthase and alcohol dehydrogenase zinc atoms. This is despite the fact that none of these enzymes have any structural or sequence similarity throughout their length. Given this positional similarity, we expect that the ammonium ion we see in MIP synthase has a role that is analogous to that seen in the other two enzymes, which is to act as a Lewis acid stabilizing negative charge on an oxygen atom.
DgtolP binding by MIP synthase involves both residues that were ordered in both structures and additional residues that become ordered upon inhibitor binding (Figs. 1a and 5a Modeling of the Aldol Cyclization and a Proposal for the Mechanism of MIP Synthase-The conformation of dgtolP in the dgtolP⅐MIP synthase structure is clearly not representative of the conformation of the substrate during the aldol cyclization. We have performed a simple rearrangement of dgtolP in an attempt to mimic the conformation necessary for cyclization. To perform this modeling, we have assumed that the phosphate and C6 remain fixed and repositioned the inhibitor in a conformation consistent with the stereochemistry of the reaction. We have additionally arranged the 5-keto group to be oriented with the nicotinamide of NAD in a position consistent with the final reduction step. We have also assumed that the structure of the enzyme is unchanged. The result of this modeling is striking (Fig. 5c ). Absolutely conserved residues now surround the modeled inhibitor and make hydrogen bonds with all of the OH groups. In addition, the 5-keto group is well positioned to interact with the ammonium ion, and Lys 369 is in close contact with O1 of the inhibitor. Other new interactions with the inhibitor include bonds Ser 323 to O3 and O4 of the inhibitor and Asp 438 to O5. The interaction between Lys 489 to O3 remains the same. Based on this modeling, we have proposed a mechanism for the transformation catalyzed by MIP synthase (Fig. 6) . The first step involves oxidation at C5 with the substrate molecule in an extended conformation similar to that seen in our structure. Subsequently, the substrate is reoriented to the conformation shown in Fig. 6 where the phosphate-mediated enolization occurs. The developing negative charge on O5 is stabilized by the ammonium cation to catalyze this process. Nucleophilic attack by C6 on C1 is promoted by Lys 369 stabilization of the developing negative charge on O1. Subsequent protonation at O1, possibly mediated by Lys 369 , and reduction of C5 by NAD, yields the myo-1-L-inositol phosphate product. MIP synthase is therefore an example of a type III aldolase, where a monovalent cation acts as the Lewis acid in the aldol condensation. In the case of the A. fulgidus enzyme, we envision a similar mechanism, except that the ammonium ion is replaced with a zinc or manganese divalent cation, making this more characteristic of a type II aldolase. All of the other residues interacting with the substrate and proposed to be involved in the mechanism are absolutely conserved in fulgidus as well as virtually all other MIP synthases whose sequences are known. Given the presence of the divalent cation at this position, we would expect the residues corresponding to 350 -354 in A. fulgidus (255-259) to be ordered even in the absence of inhibitor or substrate. This would, however, still leave significant access to the active site. Verification of this proposal must await both mutational enzymology and further enzyme-inhibitor structural results.
MIP Synthase, a New Mechanism for Induced Fit?-The concept of induced fit where "the substrate causes an appreciable change in the three-dimensional relationship of the amino acids in the active site" (50) was proposed more than 40 years ago by Koshland (50, 51) . An exhaustive search of domain movements in proteins categorizes all of these movements as either hinge movements or shear movements (52) . The structures of NAD-bound and inhibitor/NAD-bound MIP synthase have revealed an extraordinary example of induced fit that complies with neither of these mechanisms. Instead, a folding event occurs where almost 60 residues become ordered upon binding to the inhibitor. Once folded, the enzyme fully encapsulates its substrate, leaving no access to the active site without unfolding some or all of this subdomain. Although there are examples of ligand-induced structural organization, such as the formation of two helices upon DNA binding in the leucine zipper proteins (53, 54) , it is highly unusual to see a refolding event of the magnitude seen here in an enzyme with a small molecule substrate. This binding mechanism seems counterintuitive but allows the enzyme to completely encapsulate its substrate in three dimensions. Encapsulation appears to be necessary for catalysis of this complex transformation. It also invites the possibility that small molecules can be used as protein folding scaffolds, both naturally and in protein engineering applications.
